Objective The Systemic Lupus International Collaborating Clinics (SLICC) group revised
and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (…

Objective To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab
plus standard therapy compared with placebo plus standard therapy in active systemic lupus …

In the US, approximately 35% of adults with systemic lupus erythematosus (SLE) have
clinical evidence of nephritis at the time of diagnosis, with an estimated total of 50–60% …

Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus
(SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE …

Background Since anecdotal series and small, prospective, controlled trials suggest that
mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable. …

Background Oral contraceptives are rarely prescribed for women with systemic lupus
erythematosus, because of concern about potential negative side effects. In this double-blind, …

Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …

Background: There is concern that exogenous female hormones may worsen disease activity
in women with systemic lupus erythematosus (SLE). Objective: To evaluate the effect of …

Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …

Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE
inception cohort. Methods. Patients in the Systemic Lupus International Collaborating Clinics …